Related references
Note: Only part of the references are listed.Tumor suppressors BTG1 and BTG2: Beyond growth control
Laurensia Yuniati et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The Oncogenic Functions of MASTL Kinase
Kamila Marzec et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma
Ayako Kawabata et al.
GYNECOLOGIC ONCOLOGY (2017)
Emerging Roles of SPINK1 in Cancer
Kati Rasanen et al.
CLINICAL CHEMISTRY (2016)
Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma
Kati Rasanen et al.
MOLECULAR CARCINOGENESIS (2016)
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary
Nozomu Yanaihara et al.
MOLECULAR CARCINOGENESIS (2016)
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
E. M. Dijkgraaf et al.
ANNALS OF ONCOLOGY (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
Ronald L. Chandler et al.
NATURE COMMUNICATIONS (2015)
Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers
Christine Mehner et al.
ONCOTARGET (2015)
TATI as a biomarker
Outi Itkonen et al.
CLINICA CHIMICA ACTA (2014)
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2014)
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Koji Taniguchi et al.
SEMINARS IN IMMUNOLOGY (2014)
Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach
Nicola Portolano et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Intraperitoneal chemotherapy: Rationale, applications, and limitations
Osama M. Al-Quteimat et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
CDK-mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer
Diana Cepeda et al.
EMBO MOLECULAR MEDICINE (2013)
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Michael S. Anglesio et al.
PLoS One (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Emma Kipps et al.
NATURE REVIEWS CANCER (2013)
Clear cell carcinoma of the ovary: A review of the literature
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development
Ulf-Hakan Stenman
ASIAN JOURNAL OF ANDROLOGY (2011)
IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
Michael S. Anglesio et al.
CLINICAL CANCER RESEARCH (2011)
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward et al.
CLINICAL CANCER RESEARCH (2011)
Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer
Wendy WeiJia Soon et al.
EMBO MOLECULAR MEDICINE (2011)
Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers
Michael P. Stany et al.
PLOS ONE (2011)
Therapeutic Targeting of SPINK1-Positive Prostate Cancer
Bushra Ateeq et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Ovarian Cancer Development and Metastasis
Ernst Langyel
AMERICAN JOURNAL OF PATHOLOGY (2010)
Hepatitis B and Hepatitis C Virus Replication Upregulates Serine Protease Inhibitor Kazal, Resulting in Cellular Resistance to Serine Protease-Dependent Apoptosis
Jason Lamontagne et al.
JOURNAL OF VIROLOGY (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Minigene analysis of intronic variants in common SPINK1 haplotypes associated with chronic pancreatitis
E. Kereszturi et al.
GUT (2009)
Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis
Xuanyong Lu et al.
APOPTOSIS (2008)
The role of SPINK1 in ETS rearrangement-negative prostate cancers
Scott A. Tomlins et al.
CANCER CELL (2008)
Anoikis resistance and tumor metastasis
Craig D. Simpson et al.
CANCER LETTERS (2008)
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2008)
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
M. Takano et al.
BRITISH JOURNAL OF CANCER (2006)
Treatment issues in clear cell carcinoma of the ovary: A different entity?
Dimitrios Pectasides et al.
ONCOLOGIST (2006)
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine
MB Nilsson et al.
CANCER RESEARCH (2005)
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer:: Prognostic study on tissue and serum
A Paju et al.
CLINICAL CANCER RESEARCH (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
